# Titrating-Dose of Lonafarnib in Combination With Ritonavir

> **NCT02527707** · PHASE2 · COMPLETED · sponsor: **Eiger BioPharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Chronic Delta Hepatitis

## Interventions

- **DRUG:** lonafarnib
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT02527707
- **Lead sponsor:** Eiger BioPharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-08
- **Final completion:** 2017-02-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02527707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02527707, "Titrating-Dose of Lonafarnib in Combination With Ritonavir". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02527707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*